Hospira's Precedex Phase IV Trial Postponed To 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
The post-marketing safety study is being revised with FDA input. The sedative Precedex makes up only a small portion of Hospira's specialty injectables sales, which totaled $235 mil. in the U.S. for the third quarter.
You may also be interested in...
Hospira Spins Off With $4.2 Bil. Market Cap; Abbokinase Stays With Abbott
Abbott initially pegged Abbokinase as one of its hospital-based products to be divested with Hospira, but later decided the drug had a more strategic fit with the rest of its Rx portfolio.
Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.
RiskMAP Guidance Includes Plans For A Website
FDA is planning to develop a Risk Minimization Action Plan website, an agency risk management guidance states